SCHEDULE: State Street Discloses 5.1% Stake in Arcutis Biotherapeutics

State Street Corporation has reported beneficial ownership of 5.1% of Arcutis Biotherapeutics Inc.'s common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 6,296,197 shares of Arcutis Biotherapeutics Inc. common stock.
• This ownership stake represents 5.1% of the class of securities.
• The filing date for this event is March 31, 2026.
• State Street Corporation holds shared power to vote and dispose of these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a routine ownership disclosure by a large institutional investor and does not provide performance insights into Arcutis Biotherapeutics.

Positives

• State Street Corporation's significant stake suggests confidence in Arcutis Biotherapeutics' long-term prospects.
• The filing indicates a substantial institutional investor holding a notable percentage of the company's stock.

Negatives

• The filing does not contain specific financial performance data for Arcutis Biotherapeutics, only ownership details.
• No forward-looking statements or management commentary regarding Arcutis Biotherapeutics' performance are included in this filing.

Risks

• As a Schedule 13G filing, it primarily reports passive ownership and does not inherently detail specific risks related to Arcutis Biotherapeutics' business operations or market position.
• The risk for State Street Corporation would be related to the performance of Arcutis Biotherapeutics' stock, which is subject to market volatility and company-specific factors not detailed here.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance regarding Arcutis Biotherapeutics' future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings from major institutional investors like State Street Corporation are common disclosures for significant passive holdings and can signal institutional interest in a company's stock.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by State Street Corporation may be viewed positively, potentially indicating increased investor confidence.
• Management of Arcutis Biotherapeutics: The filing confirms a substantial passive investor, which can influence board dynamics and strategic considerations.
• Potential Investors: This filing provides information about the ownership structure, indicating a notable institutional presence.

Next Steps

• State Street Corporation will continue to monitor its holdings in Arcutis Biotherapeutics.
• Arcutis Biotherapeutics will continue its business operations, subject to market conditions and strategic execution.

Key Dates

Keywords

Schedule 13G, State Street Corporation, Arcutis Biotherapeutics, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing